From Static Capacity to Adaptive Networks: Building Resilience into Biologics Supply
Historically, biopharma supply chain disruptions were treated as isolated logistical hurdles. Today, they can pose systemic threats to clinical timelines, commercial launch readiness, and patient care.
Providing insights for Contract Pharma, Vice President and Head of US Sales Jeff Mason details why leading drug developers are moving away from static bioreactor capacity. Instead, they are evaluating CDMO partners on network-wide resilience, geographic agility, and the technical capability to handle modern molecular complexity.
Discover how adaptive manufacturing networks are redefining biopharma supply security.
Read the full article on Contract Pharma.
Historically, biopharma supply chain disruptions were treated as isolated logistical hurdles. Today, they can pose systemic threats to clinical timelines, commercial launch readiness, and patient care.
Providing insights for Contract Pharma, Vice President and Head of US Sales Jeff Mason details why leading drug developers are moving away from static bioreactor capacity. Instead, they are evaluating CDMO partners on network-wide resilience, geographic agility, and the technical capability to handle modern molecular complexity.
Discover how adaptive manufacturing networks are redefining biopharma supply security.
Read the full article on Contract Pharma.
Share article
Related Content